Circular 09 March 2026: Cisatracurium Injection Supply Constraints and Proposed Therapeutic Alternatives
The Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends cisatracurium as a non-depolarising muscle relaxant (NDMR) in patients with renal or liver impairment. The contracted supplier of cisatracurium, Accord Healthcare (Pty) Ltd, is however currently unable to meet their contract obligation resulting in supply constraints. Accord Healthcare (Pty) Ltd has i
The Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends cisatracurium as a non-depolarising muscle relaxant (NDMR) in patients with renal or liver impairment. The contracted supplier of cisatracurium, Accord Healthcare (Pty) Ltd, is however currently unable to meet their contract obligation resulting in supply constraints.
Accord Healthcare (Pty) Ltd has indicated that the third-party manufacturer has discontinued the production of cisatracurium and efforts are underway to identify and secure an alternative manufacturer. However, timelines for restoration of supply remain uncertain. Please refer to the document below for proposed alternatives.